Close Menu

NEW YORK – Bridge Biotherapeutics said on Thursday that the company filed an Investigational New Drug Application with both the US Food and Drug Administration and the Ministry of Food and Drug Safety in Korea in order to start clinical studies of its targeted lung cancer drug candidate BBT-176.

The drug is designed to tackle EGFR C797S resistance mutations that arise in NSCLC patients after treatment with third-generation tyrosine kinase inhibitors (TKIs).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.